BKM120
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment for Metastatic or Locally Advanced Cervical Cancer
Conditions
Treatment for Metastatic or Locally Advanced Cervical Cancer
Trial Timeline
Nov 1, 2015 → Sep 1, 2017
NCT ID
NCT01613677About BKM120
BKM120 is a phase 2 stage product being developed by Novartis for Treatment for Metastatic or Locally Advanced Cervical Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01613677. Target conditions include Treatment for Metastatic or Locally Advanced Cervical Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01613677 | Phase 2 | Withdrawn |
| NCT02220855 | Phase 2 | Completed |
| NCT01550380 | Phase 2 | Withdrawn |
| NCT01695473 | Phase 2 | Terminated |
| NCT02128724 | Phase 1 | Completed |
| NCT01833169 | Phase 2 | Completed |
| NCT01513356 | Phase 1 | Completed |
| NCT01626209 | Phase 1 | Completed |
| NCT01396499 | Phase 1 | Completed |
| NCT01629615 | Phase 2 | Completed |
| NCT01501604 | Phase 2 | Withdrawn |
| NCT01727128 | Phase 1 | Completed |
| NCT01339052 | Phase 2 | Completed |
| NCT01385293 | Phase 2 | Terminated |
| NCT01297491 | Phase 2 | Completed |
| NCT01289041 | Phase 2 | Completed |
| NCT01283503 | Phase 1 | Completed |
| NCT01068483 | Phase 1 | Completed |
Competing Products
20 competing products in Treatment for Metastatic or Locally Advanced Cervical Cancer